Nucleic Acid, Nucleoside, or Nucleotide – Page 8

FTC Supports FDA’s Simplified Biosimilar Interchangeability Plan

8 months ago talkbio0Tagged Biosimilars, interchangeable, Pharmaceutical competition, United States Federal Trade Commission, United States Food and Drug Administration

biosimilars, interchangeable biosimilars, FDA, FTC, pharmaceutical competition, drug pricing

Syros Discontinues Mid-Stage Tamibarotene Program in Frontline Acute Myeloid Leukemia (AML)

9 months ago talkbio0Tagged Agonist, azacitidine, Clinical Trials, Futility Analysis, Leukemia, Myelocytic, Acute, RARα, SELECT-AML-1, Syros Pharmaceuticals, tamibarotene, venetoclax

Syros Pharmaceuticals, Tamibarotene, Acute Myeloid Leukemia (AML), Clinical Trial, SELECT-AML-1, Venetoclax, Azacitidine, RARα Agonist, Futility Analysis

Biotech Startup Airna Secures $60M to Advance RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency

9 months ago talkbio0Tagged ADAR gene, Airna, alpha 1-Antitrypsin Deficiency, Alpha-1, Antitrypsin Deficiency, Clustered Regularly Interspaced Short Palindromic Repeats, Genetic Medicine, RNA Editing, RNA therapy, startup

Airna, RNA editing, alpha-1 antitrypsin deficiency, AATD, biotech startup, genetic medicine, ADAR, CRISPR, RNA therapy

BioNTech-Regeneron vs. Moderna-Merck.Cancer Vaccine and PD-1 Inhibitor Combinations.

9 months ago talkbio0

, BioNTech, Regeneron, Moderna, Merck, Cancer Vaccine, PD-1 Inhibitor, mRNA Technology, Melanoma, Immunotherapy, Clinical Trials,

BioNTech and Regeneron Achieve Positive Phase II Results for mRNA Cancer Vaccine Combo in Melanoma

9 months ago talkbio0

BioNTech, Regeneron, mRNA cancer vaccine, melanoma, Phase II trial, Libtayo, cemiplimab, BNT111, immunotherapy

BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111

9 months ago talkbio0Tagged BioNTech, Cancer Therapeutic Procedure, cemiplimab, checkpoint inhibitor, melanoma, mRNA immunotherapy, mRNA-LPX technology, PDCD1 gene, Phase 2 trial, Regeneron, Tetravalent RNA-lipoplex Cancer Vaccine BNT111, uridine

BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology

BioNTech and Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma

9 months ago talkbio0Tagged BioNTech, cemiplimab, Libtayo, melanoma, mRNA cancer, Phase 2 Clinical Trials, Regeneron, Tetravalent RNA-lipoplex Cancer Vaccine BNT111, Vaccines

BioNTech, Regeneron, mRNA cancer vaccine, Phase II trial, melanoma, BNT111, cemiplimab, Libtayo

GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines

9 months ago talkbio0Tagged bioplatform companies, Drug Discovery, Flagship, Immunology, Partnership, Pfizer, Pioneering, Respiration Disorders, RNA, Messenger, SmithKline Beecham, Vaccines

GSK, Flagship Pioneering, drug discovery, vaccines, respiratory disease, immunology, bioplatform companies, mRNA vaccines, Pfizer, biotech partnership